Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study

Thoracic Cancer
Chengping HuWendong Chen

Abstract

Previously reported superior tumor response of pemetrexed in the second-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) has never been confirmed in real-world studies. Platinum-based doublet is frequently used in the second-line setting for advanced NSCLC in China. A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. Propensity score matched treatment groups were created for head-to-head comparisons on best tumor response and clinical toxicity. Multiple regression analyses were performed to rank the impact of the four regimens on the risks of tumor progression and hematological adverse events. Three hundred and eighty-four patients were included for creating matched treatment groups for pemetrexed versus platinum/pemetrexed (33 pairs), docetaxel (17 pairs), and platinum/docetaxel (29 pairs), respectively. No significant differences were identified for best tumor response between pemetrexed and the other three regimens. However, pemetrexed was associated with significantly fewer patients experiencing anemia (39.4% vs. 69.7%, P = 0.004) and neutropenia (6...Continue Reading

References

Jan 24, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Tatsuo NakagawaFumihiro Tanaka
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 15, 2004·Journal of Epidemiology and Community Health·Miguel Delgado-Rodríguez, Javier Llorca
Feb 8, 2005·Ai zheng = Aizheng = Chinese journal of cancer·Fei-Yue FengYou-Sheng Mao
Feb 20, 2007·Molecular Cancer Therapeutics·Shrikanta ChattopadhyayI David Goldman
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo Di MaioCesare Gridelli
Jul 23, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter H O'Donnell, M Eileen Dolan
Aug 5, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sai-Hong Ignatius OuJason A Zell
Dec 2, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Giorgio ScagliottiChandra P Belani
Feb 15, 2011·Biomedical and Environmental Sciences : BES·Yan YangGong-Huan Yang
Jul 22, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Dolores IslaHenrik W Finnern
Sep 14, 2011·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jing ZhangChun-Xue Bai
Apr 14, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·R PirkerU Gatzemeier
May 15, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Cong XueLi Zhang
Nov 28, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Y SunX-Q Zhang
Dec 18, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Daniel C ChristophFred R Hirsch
Dec 19, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Ke ChengJi-Yan Liu
Apr 3, 2013·Chest·Jun SheChunxue Bai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.